Business Context and Reporting Period
This Form 8-K is a current report filed by Spero Therapeutics, Inc. on September 9, 2020. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol SPRO. The filing addresses a specific corporate event regarding its equity financing arrangements.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial metric disclosed relates to the company's "At-the-Market" (ATM) equity offering:
- ATM Offering Capacity: Up to $50,000,000 (authorized under the December 3, 2018 Sales Agreement).
- Shares Sold to Date: $15,419,270.41.
- Remaining Capacity: Approximately $34,580,729.59 (calculated based on disclosed figures).
Material Changes
The primary material change reported is the termination of the ATM Prospectus Supplement effective September 9, 2020. While the underlying Sales Agreement with Cantor Fitzgerald & Co. remains in full force and effect, the Company has ceased sales under the current prospectus supplement. No further sales of common stock can be made under this ATM Offering until an updated prospectus supplement is filed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the immediate cessation of the ATM sales program. The termination of the prospectus supplement implies a strategic pause in utilizing this specific capital-raising mechanism until regulatory documentation is updated.
Investor Verification Checklist
- Verify the status of the updated prospectus supplement to determine when ATM sales may resume.
- Review recent 10-Q or 10-K filings for the company's current cash position and burn rate, as this 8-K does not provide liquidity data.
- Confirm if the termination of the ATM program impacts the company's ability to fund ongoing clinical trials or operations.
- Check for any concurrent press releases explaining the rationale behind terminating the prospectus supplement.